Filing Details
- Accession Number:
- 0001209191-18-007403
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-05 16:01:30
- Reporting Period:
- 2018-02-01
- Accepted Time:
- 2018-02-05 16:01:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-02-01 | 11,250 | $0.00 | 24,905 | No | 4 | A | Direct | |
Common Stock | Acquisiton | 2018-02-02 | 4,000 | $5.50 | 28,905 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-02-02 | 2,600 | $201.91 | 26,305 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-02-02 | 1,400 | $203.20 | 24,905 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Acquisiton | 2018-02-01 | 45,000 | $0.00 | 45,000 | $205.25 |
Common Stock | Stock Option (right to buy) | Disposition | 2018-02-02 | 4,000 | $0.00 | 4,000 | $5.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
45,000 | 2028-02-01 | No | 4 | A | Direct | |
67,951 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2019, 25% on 01/04/2020, 25% on 01/04/2021, and 25% on 01/04/2022.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.
- The range of prices for the transaction reported on this line was $201.55 to $202.45. The average weighted price was $201.9065. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range of prices for the transaction reported on this line was $202.95 to $203.50. The average weighted price was $203.2032. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2019, and in 36 equal monthly installments.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.